Quelle: Medline Abstract Fachblatt Ann Intern Med.

Wechseljahre:  Pflanzliche Medikamente, die Extrakte aus der Traubensilberkerze enthalten wirken bei der Therapie typischer Wechseljahrsbeschwerden nicht besser als ein unwirksames Scheinmedikament.

An der Universität von Washington wurde untersucht, ob aus dem  Traubensilberkerzenrhizom gewonnene Wirkstoffe in der Lage sind, die für die Wechseljahre der Frau typischen vasomotorischen Symptome (z.B. Hitzewallungen) zu bessern. Die in den Annals of Internal Medicine publizierte Untersuchung wurde unter Beteiligung von 351 Frauen (52% Frauen in der Menopause und 48% in der Postmenopause) als Doppelblind-Studie konzipiert und durchgeführt. Die Frauen klagten im Schnitt über 2 oder mehr "Hitzewallungen" pro Tag. Im Verlauf der Untersuchung konnten nach 3, 6 und 12 Monaten keine statistisch signifikanten Unterschiede zwischen den Therapiegruppen und den Anwenderinnen der Scheinmedikamente (Placebo) gefunden werden.

weitere Informationen zum Thema:

Therapiestudie 2006 Mayo Clinic and Mayo Foundation mehr

Cimicifugae racemosae rhizoma - Traubensilberkerzenwurzelstock mehr

Ann Intern Med. 2006 Dec 19;145(12):869-79.

Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.

Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J.

Group Health Center for Health Studies, the University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98101, USA. newton.k@ghc.org

BACKGROUND: Herbal supplements are widely used for vasomotor symptoms.

OBJECTIVE: To test the efficacy of 3 herbal regimens and hormone therapy for relief of vasomotor symptoms compared with placebo.

DESIGN: 1-year randomized, double-blind, placebo-controlled trial conducted from May 2001 to September 2004.

SETTING: Group Health, Washington State.

PARTICIPANTS: 351 women age 45 to 55 years with 2 or more vasomotor symptoms per day; 52% of the women were in menopausal transition and 48% were postmenopausal.

MEASUREMENTS: Rate and intensity of vasomotor symptoms (1 = mild to 3 = severe), and Wiklund Vasomotor Symptom Subscale.

INTERVENTIONS: 1) Black cohosh, 160 mg daily; 2) multibotanical with black cohosh, 200 mg daily, and 9 other ingredients; 3) multibotanical plus dietary soy counseling; 4) conjugated equine estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily; or 5) placebo.

RESULTS: Vasomotor symptoms per day, symptom intensity, Wiklund Vasomotor Symptom Subscale score did not differ between the herbal interventions and placebo at 3, 6, or 12 months or for the average over all the follow-up time points (P > 0.05 for all comparisons) with 1 exception: At 12 months, symptom intensity was significantly worse with the multibotanical plus soy intervention than with placebo (P = 0.016). The difference in vasomotor symptoms per day between placebo and any of the herbal treatments at any time point was less than 1 symptom per day; for the average over all the follow-up time points, the difference was less than 0.55 symptom per day. The difference for hormone therapy versus placebo was -4.06 vasomotor symptoms per day for the average over all the follow-up time points (95% CI, -5.93 to -2.19 symptoms per day; P < 0.001).

LIMITATIONS: The trial did not simulate the whole-person approach used by naturopathic physicians. Differences between treatment groups smaller than 1.5 Vasomotor symptoms per day cannot be ruled out.

CONCLUSION: Black cohosh used in isolation, or as part of a multibotanical regimen, shows little potential as an important therapy for relief of vasomotor symptoms.

Clinical Trials Registration number: NCT00169299.